ALKS Alkermes plc
Alkermes plc (ALKS) is expected to report earnings on October 27, 2026, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.7% since its last earnings release on July 28, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Alkermes plc
Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.
Sector
Healthcare
Industry
Drug Manufacturers/Other